Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial
HR Black, WJ Elliott, G Grandits, P Grambsch… - Jama, 2003 - jamanetwork.com
ContextHypertensive patients are often given a calcium antagonist to reduce cardiovascular
disease risk, but the benefit compared with other drug classes is controversial. ObjectiveTo
determine whether initial therapy with controlled-onset extended-release (COER) verapamil
is equivalent to a physician's choice of atenolol or hydrochlorothiazide in preventing
cardiovascular disease. Design, Setting, and ParticipantsDouble-blind, randomized clinical
trial conducted at 661 centers in 15 countries. A total of 16 602 participants diagnosed as …
disease risk, but the benefit compared with other drug classes is controversial. ObjectiveTo
determine whether initial therapy with controlled-onset extended-release (COER) verapamil
is equivalent to a physician's choice of atenolol or hydrochlorothiazide in preventing
cardiovascular disease. Design, Setting, and ParticipantsDouble-blind, randomized clinical
trial conducted at 661 centers in 15 countries. A total of 16 602 participants diagnosed as …
